




Georges Ephrem
253 posts
































Late-breaking trial at #CRT2026: Tirzepatide after TAVR substanially reduced HALT and PVL at 12 months. Highlights: • HALT: 8.4% vs 21.6% (RR 0.39, p=0.002) • PVL: 10.7% vs 25.3% • SLT progression: 3.1% vs 11.5% • Lower mean gradient, better EOA • No unexpected safety signal A metabolic therapy entering the structural valve conversation. Next steps: further sensitivity analysis looking at the impact of the degree of weightloss on HALT? Are the results solely due to weight loss, anti-inflammatory or other mechanims? Great work by Dr. Thirugnanam and team! #TAVR #StructuralHeart #GLP1 #CardioX @crt_meeting @ron_waksman @GreggWStone @TheDoctorMack @KarenMKimMD1 @PopmaJeffrey @MReardon19 @SachinGoelMD










